

16. Mittal K. Utility of MIB-1 in evaluating cauterized cervical cone biopsy margins. *Int J Gynecol Pathol* 1999;18:211–4.
17. Rose DS, Maddox PH, Brown DC. Which proliferation markers for routine immunohistology? A comparison of five antibodies. *J Clin Pathol* 1994;47:1010–4.
18. van Hoeven KH, Kovatich AJ. Immunohistochemical staining for proliferating cell nuclear antigen, BCL2, and MIB-1 in vulvar tissues. *Int J Gynecol Pathol* 1996;15:10–6.
19. Scurry J, Beshay V, Cohen C, Allen D. Ki67 expression in lichen sclerosus of vulva in patients with and without associated squamous cell carcinoma. *Histopathology* 1998;32:399–404.
20. Modesitt SC, Groben PA, Walton LA, Fowler WC Jr, Van Le L. Expression of MIB-1 in vulvar carcinoma and vulvar intraepithelial neoplasia III: correlation with clinical prognostic factors. *Gynecol Oncol* 2000;76:51–5.
21. Isacson C, Kessis TD, Hedrick L, Cho K. Both cell proliferation and apoptosis increase with lesion grade in cervical neoplasia but do not correlate with human papillomavirus type. *Cancer Res* 1996;56:669–74.
22. Mittal K, Palazzo J. Cervical condylomas show higher proliferation than do inflamed or metaplastic cervical squamous epithelium. *Mod Pathol* 1998;11:780–3.
23. Al-Ghamdi A, Miller D, Benedet JL, Clement PB, Gilks CB. Invasive vulvar squamous cell carcinoma in young women: a clinicopathological study of 21 cases [abstract]. *Mod Pathol* 2000;13(1).
24. Soini Y, Kamel D, Paakko P, Lehto VP, Oikarinen A, Vahakangas KV. Aberrant accumulation of p53 associates with Ki67 and mitotic count in benign skin lesions. *Br J Dermatol* 1994;131:514–20.
25. Solomon D, Schiffman M, Tarone R. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. *J Natl Cancer Inst* 2001;93:293–9.

## Book Review

**Pasqualini JR, editor: *Breast Cancer: Prognosis, Treatment, and Prevention, 656 pp, New York, Marcel Dekker, Inc., 2002 (\$165.00).***

Pasqualini and colleagues have assembled a significantly unique collection of reviews in breast cancer. In 17 widely ranging chapters, only occasionally overlapping, the authors provide in-depth reviews of the many-faceted hormonal and molecular influences on breast tissue, both normal and malignant.

The authors intend their book to target oncologists, gynecologists, general clinicians, biologists, physiologists, and other advanced students. The majority of the chapters are relatively sophisticated reviews in basic science. Paradoxically, this is why the book may be most useful to clinicians whose available standard texts on breast cancer tend to emphasize reviews of clinical trials. Contrastingly, this text should gain readership from clinicians, particularly those working on the cusp of new patient-focused research, translating new molecular information into patient clinical trials.

The chapter on “BRCA-1, BRCA-2 and Hereditary Breast Cancer,” by Bove *et al.*, is particularly noteworthy; representing one of the most cogent and readable chapters on this issue the reviewer has had the good fortune to read. This chapter, as do many in this text, pushes the reader into regions of basic science that are new, and to fully understand may require some study beyond a cursory reading.

Each of the above-targeted specialists that the authors have identified can benefit from this book. But it would seem clinical researchers, particularly those doing translational research, will find this text most useful in their own endeavors. The book is recommended to those very clinical researchers and should be available in any academic library where such clinical researchers reside.

**Ronald L. Stephens**

*Lawrence Memorial Oncology Center  
Lawrence, Kansas  
University of Kansas Medical Center  
Kansas City, Kansas*